
About RenovoRx
RenovoRx is a publicly listed company based in Los Altos (United States) founded in 2009. RenovoRx has raised $10.91 million across 7 funding rounds from investors including Boston Scientific, BtoV and Astia. The company has 10 employees. RenovoRx offers products and services including RenovoCath Device and TAMP Therapy Platform. Its focus areas include Life Sciences, Drug Delivery, Intravenous and Oncology. Its legal entity is RENOVORX, INC. Its competitors include Moderna, BeiGene and Insulet; 3 of its 3 listed competitors have raised funding.
Company details
Developing endovascular catheters for targeted delivery of IV fluids to peripheral organs. It develops endovascular catheters for the visceral and peripheral vascular systems. The RenovoRx device can be used to deliver both therapeutic(such as drugs)and diagnostic fluids(such as contrast agents) to the target organ through veins. The device allows for isolated vessel perfusion i.e. a balloon is inflated within the blood vessels to block blood flow to other organs to maximize the amount of blood flow(and IV fluids reaching the target organ.
- Headquarters Los Altos, United States
- Employees 10
- Stage Public
- SectorsHealthcare
- Website renovorx.com
- Social LinkedIn X Facebook YouTube
- Legal Name Renovorx, Inc.
- Annual Revenue$1.12 M (USD)2511.63as on Dec 31, 2025
- Net Profit-$11.17 M (USD)-26.71as on Dec 31, 2025
- EBITDA-$12.51 M (USD)-14.02as on Dec 31, 2025
- Total Equity Funding$10.91M (USD)
in 7 rounds
- Latest Funding Round$10M (USD), Post-IPO
Mar 2026
- InvestorsBoston Scientific
& 8 more
- Employee Count10
Products & Services of RenovoRx
RenovoRx offers a comprehensive portfolio of products and services, including RenovoCath Device and TAMP Therapy Platform.
FDA-cleared device for targeted drug delivery in oncology treatments.
Platform for precise intra-arterial drug administration to minimize side effects.
Apps and channels of RenovoRx
its YouTube channel RNXT (RenovoRx) has 31 subscribers and 8 videos.
Videos from RenovoRx
The most watched videos on RenovoRx's YouTube channel, RNXT (RenovoRx) (31 subscribers). Click a video to play it here.
More on RNXT (RenovoRx).
Funding Insights of RenovoRx
RenovoRx has successfully raised a total of $10.91M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.91M
- Total Rounds 7
- Last Round Post-IPO — $10M
- First Round $660,000
(Apr 2013)
- Investors Count 9
All 7 funding rounds of RenovoRx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $10M | Post-IPO | – | – | – |
| Apr 2024 | $11.14M | Post-IPO | – | – | – |
| Jan 2024 | Post-IPO | – | – | – | |
| May 2018 | $7M | Series D | – | Boston Scientific | |
| Dec 2015 | $2.1M | Series C | – | – | – |
| Jan 2014 | $1.15M | Series B | – | Golden Seeds | |
| Apr 2013 | $660,000 | Series A | – | – | – |
9 investors in total: 9 institutional.
Investors in RenovoRx
RenovoRx has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Boston Scientific, BtoV and Astia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Stage agnostic VC firm funding companies in Europe | btov.vc | Berlin, Germany | ||
Women-led startups are funded through stage-agnostic investments and angel networks. | astia.org | San Francisco, United States | ||
Tech & Life Sciences focused VC firm investing in early stage startups in the US | angelsforum.com | Mountain View, United States | ||
| halofund.com | ||||
Tech & Life-Sciences focused VC Firm investing in the US | goldenseeds.com | New York, United States | ||
Early-stage life science and technology startups are supported. | acorntaiwan.com | Santa Clara, United States | ||
Angel funding is provided to Silicon Valley-based companies. | sandhillangels.com | Mountain View, United States | ||
Seed and early-stage investments are focused on US companies. | amidzad.com | Redwood City, United States | ||
Wide range of medical devices | 1979 | bostonscientific.com | Marlborough, United States |
Investor details for RenovoRx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of RenovoRx
18 people are tracked at RenovoRx (9 in leadership, 8 in board & advisors, 1 in team); the tracked headcount is 10.
| Name | Role | Group |
|---|---|---|
Robert Strasser | VP Operations And R&d | Leadership |
James Ahlers | CFO | Leadership |
Ronald B. Kocak | Vice President & Controller | Leadership |
Shaun R. Bagai | CEO | Leadership |
Ramtin Agah | Chief Medical Officer & Founder | Leadership |
Philip Stocton | Sr. Global Director Sales And Market Developemnt | Leadership |
Imtiaz Qureshi | Director, Imaging | Leadership |
Neil Sankar M.D.,MPH | Sr Medical Director and Medical Monitor Consultant Medical Oncology Programs | Leadership |
Ryan Witt | Svp, Head Of Corporate Strategy & Partnerships | Leadership |
Una S. Ryan | Director | Board & advisors |
Laurence J. Marton | Director | Board & advisors |
Mike Pishvaian | Advisor | Board & advisors |
Margaret A. Tempero | Scientific Advisory Board Member | Board & advisors |
Angela MacFarlane | Director | Board & advisors |
David Diamond | Director | Board & advisors |
Karyn A. Goodman | Advisor | Board & advisors |
Robert J. Spiegel | Director | Board & advisors |
Leesa Gentry | SVP, Clinical Operations | Team |
Complete people profiles for RenovoRx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of RenovoRx
RenovoRx is a publicly listed company on the NASDAQ with ticker symbol RNXT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Aug 2021
- Listed onNASDAQ: RNXT
- Listed entityRenovoRx, Inc.
- Exchange sectorHealth technology
- ISINUS75989R1077
- Share price$1.15 (-8% on the day) · 2026-10-13
- Market capitalisation$51.9M
- EPS (diluted, trailing year)$-0.31
- Volume (last session)942,432
Financials of RenovoRx
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.1M | -$11.2M | -$12.5M |
| 2024 | $43,000 | -$8.8M | -$11.0M |
| 2023 | -$10.2M | -$11.4M | |
| 2022 | -$9.9M | -$9.9M | |
| 2021 | -$6.3M | -$5.7M |
Detailed financial statements for RenovoRx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of RenovoRx
4 dated milestones of RenovoRx across 17 years, from founding to its latest funding, stage changes and deals.
- Founded RenovoRx is founded.
- Funding First funding round of $660K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $10.0M.
Competitors of RenovoRx
RenovoRx has 3 listed competitors in our database, 3 of them funded. They include Moderna, BeiGene and Insulet.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| insulet.com | 2000 | Boston, United States | $120.4M | 2,600 | Wearable insulin infusion systems are developed for diabetes patients. |
Detailed competitors of RenovoRx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of RenovoRx
The website of RenovoRx (renovorx.com) receives about 6K visits a month.
- Monthly visits6K
▲ 70.7% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as RenovoRx (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Renovorx
Complete news archive for RenovoRx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RenovoRx
RenovoRx was founded in 2009 and raised its 1st funding round 4 years after it was founded.
RenovoRx is headquartered in Los Altos, United States. It is registered at Los Altos, California, United States.
RenovoRx is a funded company, having raised a total of $10.91M across 7 funding rounds to date. The company's 1st funding round was a Series A of $660K, raised on Apr 2013.
RenovoRx has 10 employees.
Annual revenue of RenovoRx is $1.12M as on Dec 31, 2025.
Developing endovascular catheters for targeted delivery of IV fluids to peripheral organs. It develops endovascular catheters for the visceral and peripheral vascular systems. The RenovoRx device can be used to deliver both therapeutic(such as drugs)and diagnostic fluids(such as contrast agents) to the target organ through veins. The device allows for isolated vessel perfusion i.e. a balloon is inflated within the blood vessels to block blood flow to other organs to maximize the amount of blood flow(and IV fluids reaching the target organ.
RenovoRx offers RenovoCath Device and TAMP Therapy Platform.
Yes, RenovoRx is publicly traded on NASDAQ under the ticker symbol RNXT.
RenovoRx has 9 investors. Key investors include Boston Scientific, BtoV, Astia, The Angels’ Forum, and The Halo Fund.
RenovoRx operates through Renovorx, Inc..
